Spin offs

<p>Logo Nostrum Biodiscovery</p>

Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and, specifically, in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of new therapeutic strategies based on peptidic protease inhibition. Iproteos is developing peptidic protease inhibitors for the treatment of CNS diseases.

IRB Barcelona Spin offs

Innovation projects

Innovation projects

<p>Institució Cerca</p>

The Premi Pioner seeks to recognize researchers at CERCA centres who, in the last 18 months, have defended a doctoral thesis that has a clear orientation towards launching or strengthening a technology or product of industrial or commercial interest or that can make a significant contribution to the development of public policies. In 2015, Benjamí Oller, former PhD student in Prof. Ernest Giralt’s lab, was awarded this prize for his thesis, entitled “From bee venom to blood-brain barrier shuttles. Development of minimized apamin derivatives for brain delivery of antibodies and other cargoes”.

More information on this news.

The type of high-risk/high-gain research at the frontiers of knowledge that the ERC promotes often generates unexpected or new opportunities for commercial and societal applications. The ERC is committed to ensure the full exploitation of the excellent, useful ideas it funds. The Proof of Concept funding helps ERC grant-holders bridge the gap between their research and the earliest stage of a marketable innovation.

 

VALUNI 2015 aims to encourage action plans of marketing units to promote technology commercialization via the licensing of patents and/or creation of technology-based companies. Furthermore, it seeks to strengthen technology projects and marketing activities in order to ensure effective technology transfer to the productive sector. The Innovation Department was granted this funding for the project INNOVal 2015.

 

News

<p>Despite the expanding repertoire of new anti-cancer agents, treatment failure remains a major challenge in the management of most advanced solid tumours, including breast cancer.</p>
20 Des 2016

Un anàlisi exhaustiu fet in silico d’aparellar els 64 agents terapèutics desenvolupats per tractar el càncer de mama –la meitat en ús i la meitat en fase clínica- ha permès a investigadors

<p>Iproteos is currently performing the regulatory preclinical phase of its drug candidate for CIAS treatment.</p>
19 Des 2016

La biotecnològica Iproteos i l'IRB Barcelona, en col·laboració amb el Grup de Neuropsicofarmacologia de la Universitat del País Basc (UPV/EHU)

<p>Group leader Salvador Aznar Benitah and first author Gloria Pascual in the Stem Cells and Cancer lab at the IRB Barcelona (M. Minocri, IRB Barcelona)</p>
7 Des 2016

Un estudi publicat avui a Nature liderat per l'investigador ICREA de l'Institut de Recerca Biomèdica (IRB Barcelona),

<p>The initiative aims to raise 25,000 euros to fund the first year of a PhD student at IRB Barcelona (L.T. Barone, IRB Barcelona)</p>
16 Nov 2016

L’Institut de Recerca Biomèdica (IRB Barcelona) inicia avui la campanya “Futur” (#IRBfutur) per un període de dos

Testimonial

Contacte

Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193